in part ii , item 1a . of this annual report on form 10-k. we base our forward-looking statements on information currently available to us , and we undertake no obligation to update or revise any forward-looking statements , whether as a result of changes in underlying factors , new information , future events or otherwise . the following should be read in conjunction with our consolidated financial statements and “ item 1. business ” . company overview the company consists of two major divisions , kidney care and healthcare partners ( hcp ) . kidney care is comprised of our u.s. dialysis and related lab services , our ancillary services and strategic initiatives , including our international operations , and our corporate support costs . our u.s. dialysis and related lab services business is our largest line of business , which is a leading provider 59 of kidney dialysis services in the u.s. for patients suffering from chronic kidney failure , also known as esrd . our hcp division is a patient- and physician-focused integrated health care delivery and management company with nearly three decades of providing coordinated , outcomes-based medical care in a cost-effective manner . our overall financial performance was once again strong for 2014 , and was characterized by strong treatment volume growth , primarily from acquisitions and non-acquired growth rates , cost control initiatives and productivity improvements in our dialysis business , and solid growth in hcp 's senior capitated members . however , hcp experienced a significant reduction in medicare advantage reimbursement rates in 2014 , which negatively impacted its operating income . in addition , our dialysis segment experienced a large increase in our pharmaceutical costs . some of our major accomplishments and financial operating performance indicators in 2014 and year over year were as follows : · improved clinical outcomes in our u.s. dialysis operations ; · consolidated net revenue growth of approximately 8.8 % . a 5.8 % revenue growth related to our u.s. dialysis segment operations and an increase of 9.6 % in our hcp segment operations ; · an increase of approximately 5.7 % in the overall number of u.s. dialysis related treatments ; · normalized non-acquired u.s. dialysis treatment growth of 5.0 % ; · consolidated operating income growth of approximately 17.1 % ; · an increase of 72,800 in hcp 's senior capitated members ; · added a net total of 105 u.s. dialysis centers and added a total of 18 international dialysis centers ; and · strong operating cash flows of $ 1.459 billion , which have been reduced by approximately $ 269 million of after-tax payments made in connection with the settlement of the 2010 and 2011 u.s. attorney physician relationship investigations . however , we face uncertainty and various challenges in 2015 as we undertake initiatives to mitigate increases in clinical costs that we expect to experience due to inflation and other factors without any corresponding increase in our dialysis medicare reimbursement rates . in addition , congress could still make significant changes to medicare and medicaid under the health care reform legislation that was enacted in the u.s. and there is uncertainty around the potential negative impact of healthcare insurance exchanges . physician practices of prescribing pharmaceuticals and pharmaceutical costs could also have a significant impact on our operating results . we also remain committed to our international expansion plans that will continue to require investment . in addition , if the percentage of our dialysis patients with commercial payors continues to deteriorate or if we experience a decrease in our overall commercial rates , our operating results could be adversely affected . hcp also faces uncertainty in medicare advantage reimbursement rates as the government continues to modify adjustments to the rates . see hcp 's “ net revenues section ” for further details . 60 following is a summary of consolidated operating results for reference in the discussion that follows . the operating results of hcp are included in our operating results effective november 1 , 2012. replace_table_token_7_th the following table summarizes consolidated net revenues : replace_table_token_8_th 61 the following table summarizes consolidated operating income and adjusted consolidated operating income : replace_table_token_9_th ( 1 ) for the years ended december 31 , 2014 and 2013 , we have excluded $ 17 million and $ 397 million , respectively , of accruals related to a loss contingency reserve for the settlement of the 2010 and 2011 u.s. attorney physician relationship investigations . in 2013 , we have also excluded $ 57 million related to a decrease in hcp 's 2013 contingent earn-out obligation and an adjustment of $ 8 million to reduce a tax asset associated with the hcp acquisition escrow provisions . for the year ended december 31 , 2012 , we have excluded $ 86 million of expenses related to a legal settlement and we have also excluded $ 31 million of transaction expenses associated with the acquisition of hcp from operating expenses and operating income . these are non-gaap measures and are not intended as substitutes for the gaap equivalent measures . we have presented these adjusted amounts because management believes that these presentations enhance a user 's understanding of our normal consolidated operating income by excluding certain unusual items which we do not believe are indicative of our ordinary results of operations . as a result , adjusting of these amounts allows for comparison to our normal prior period results . story_separator_special_tag in 2014 , we continued to enter into some commercial contracts covering certain patients that will primarily pay us a single bundled payment rate for all dialysis services provided to these patients . we are continuously in the process of negotiating agreements with our commercial payors , and payors are aggressive in their negotiations . if our negotiations result in overall commercial rate reductions in excess of overall commercial rate increases , this would have a material adverse effect on our operating results . in addition , if there are job losses in the u.s. as a result of a downturn in the economy , or depending upon changes to the healthcare regulatory system , including the impact of health care insurance exchanges , we could experience a decrease in the number of patients covered under commercial plans . approximately 3 % of our dialysis and related lab services revenues for the year ended december 31 , 2014 , were from physician-prescribed pharmaceuticals that are separately billable , with epo accounting for approximately 2 % of our dialysis and related lab services revenues . the impact of physician-prescribed pharmaceuticals on our overall revenues that are separately billable has significantly decreased from prior years primarily as a result of medicare 's single bundled payment system , as well as some additional commercial contracts that pay us a single bundled payment rate . our operating performance with respect to dialysis services billing and collection can also be a significant factor in the average dialysis and related lab services revenue per treatment we recognize and are able to collect . over the past several years we have invested heavily in upgrades to our systems and internal processes that we believe have helped improve our operating performance and reduced our regulatory compliance risks , and we expect to continue to improve these systems and processes . in 2014 , we continued to upgrade our 65 information technology systems and implemented process changes . we are currently upgrading our billing and other systems and modifying our processes to improve our ability to capture the necessary patient characteristics , co-morbidities and certain other factors under medicare 's bundled payment system . we believe this will potentially enable us to capture additional reimbursement amounts from medicare and enhance our overall billing and collection performance . however , as we continue to make upgrades to our systems and processes , or as payors change their systems and requirements , such as changes to medicare 's billing codes , we could experience a negative impact to our cash collection performance which would affect our average dialysis and related lab services revenue per treatment . our dialysis and related lab services revenue recognition involves significant estimation risks . our estimates are developed based on the best information available to us and our best judgment as to the reasonably assured collectability of our billings as of the reporting date based upon our actual historical collection experience . changes in estimates are reflected in the then-current period financial statements based upon on-going actual experience trends , or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies . our annual average dialysis and related lab services revenue per treatment was approximately $ 342 , $ 340 and $ 332 for 2014 , 2013 and 2012 , respectively . in 2014 , the average dialysis and related lab services revenue per treatment increased by approximately $ 2 per treatment primarily from the recognition of certain california medicaid revenue that was previously reserved , an increase in some of our commercial payment rates , partially offset by changes in our commercial payor mix . in 2013 , the average dialysis and related lab services revenue per treatment increased by approximately $ 8 per treatment primarily due to an increase in our medicare reimbursements , net of the impact of sequestration , and an increase in some of our commercial payment rates , partially offset by changes in the commercial payor mix , and a decline in the intensities of physician-prescribed pharmaceuticals that are billed separately . our average dialysis and related lab services revenue per treatment can be significantly impacted by several major factors , including our commercial payment rates ; government payment policies regarding reimbursement amounts for dialysis treatments and pharmaceuticals under medicare 's bundled payment rate system , including our ability to capture certain patient characteristics ; changes in the mix of government and commercial patients , including the number of commercial patients that are either covered under commercial contracts or are out of network ; and changes in the mix and intensities of physician-prescribed pharmaceuticals that are billed separately . the principal drivers of our dialysis and related lab services patient care costs are clinical hours per treatment , labor rates , vendor pricing of pharmaceuticals , utilization levels of pharmaceuticals , business infrastructure costs , which include the operating costs of our dialysis centers , and certain professional fees . however , other cost categories can also represent significant cost variability , such as employee benefit costs , payroll taxes , insurance costs and medical supply costs . our average clinical hours per treatment or productivity levels in 2014 improved slightly compared to 2013 , which was primarily the result of improvements in our internal procedures and processes . we are always striving for improved productivity levels , however , changes in federal and state policies or regulatory billing requirements can lead to increased labor costs in order to implement these new requirements , which can adversely impact our ability to achieve optimal productivity levels . in addition , improvements in the u.s. economy have stimulated additional competition for skilled clinical personnel resulting in slightly higher teammate turnover in 2014 , which we believe negatively affected productivity levels . in 2014 and 2013 , we experienced an increase in our clinical labor rates of approximately 1.5 % and 2.0 % , respectively , as clinical

available liquidity . as of december 31 , 2014 , our cash balance was $ 965 million and we also had approximately $ 337 million in short-term investments . we also had an undrawn revolving line of credit under our senior secured credit facilities totaling $ 1.000 billion , of which approximately $ 95 million was committed for outstanding letters of credit . in addition , hcp has an outstanding letter of credit of approximately $ 1.3 million that is secured by a certificate of deposit . we believe that we will have sufficient liquidity , operating cash flows and access to borrowings to fund our scheduled debt service payments and other obligations for the foreseeable future . our primary sources of liquidity are cash from operations and cash from borrowings . cash flow from operations during 2014 amounted to $ 1.459 billion , compared with $ 1.773 billion for 2013. the decrease in our operating cash flows in 2014 as compared to 2013 was primarily due to the payments of approximately $ 410 million , or $ 269 million after-tax , made in connection with the settlement of the 2010 and 2011 u.s. attorney physician relationship investigations and additional income tax payments , partially offset by the timing of other working capital items and improved cash collections which 77 resulted in a decrease in our u.s. dialysis and related lab services dso from 55 days to 50 days . cash flow from operations in 2014 included cash interest payments of approximately $ 352 million and cash tax payments of $ 239 million . cash flow from operations in 2013 included cash interest payments of approximately $ 405 million and cash tax payments of $ 341 million . non-operating cash outflows in 2014 included $ 641 million for capital asset expenditures , including $ 376 million for new center developments and relocations , and $ 265 million for maintenance and information technology . we also spent an additional $ 272 million for acquisitions . during 2014 , we also received $ 144 million from the maturity and sale of investments .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```available liquidity . as of december 31 , 2014 , our cash balance was $ 965 million and we also had approximately $ 337 million in short-term investments . we also had an undrawn revolving line of credit under our senior secured credit facilities totaling $ 1.000 billion , of which approximately $ 95 million was committed for outstanding letters of credit . in addition , hcp has an outstanding letter of credit of approximately $ 1.3 million that is secured by a certificate of deposit . we believe that we will have sufficient liquidity , operating cash flows and access to borrowings to fund our scheduled debt service payments and other obligations for the foreseeable future . our primary sources of liquidity are cash from operations and cash from borrowings . cash flow from operations during 2014 amounted to $ 1.459 billion , compared with $ 1.773 billion for 2013. the decrease in our operating cash flows in 2014 as compared to 2013 was primarily due to the payments of approximately $ 410 million , or $ 269 million after-tax , made in connection with the settlement of the 2010 and 2011 u.s. attorney physician relationship investigations and additional income tax payments , partially offset by the timing of other working capital items and improved cash collections which 77 resulted in a decrease in our u.s. dialysis and related lab services dso from 55 days to 50 days . cash flow from operations in 2014 included cash interest payments of approximately $ 352 million and cash tax payments of $ 239 million . cash flow from operations in 2013 included cash interest payments of approximately $ 405 million and cash tax payments of $ 341 million . non-operating cash outflows in 2014 included $ 641 million for capital asset expenditures , including $ 376 million for new center developments and relocations , and $ 265 million for maintenance and information technology . we also spent an additional $ 272 million for acquisitions . during 2014 , we also received $ 144 million from the maturity and sale of investments .
```    
 Suspicious Activity Report : in part ii , item 1a . of this annual report on form 10-k. we base our forward-looking statements on information currently available to us , and we undertake no obligation to update or revise any forward-looking statements , whether as a result of changes in underlying factors , new information , future events or otherwise . the following should be read in conjunction with our consolidated financial statements and “ item 1. business ” . company overview the company consists of two major divisions , kidney care and healthcare partners ( hcp ) . kidney care is comprised of our u.s. dialysis and related lab services , our ancillary services and strategic initiatives , including our international operations , and our corporate support costs . our u.s. dialysis and related lab services business is our largest line of business , which is a leading provider 59 of kidney dialysis services in the u.s. for patients suffering from chronic kidney failure , also known as esrd . our hcp division is a patient- and physician-focused integrated health care delivery and management company with nearly three decades of providing coordinated , outcomes-based medical care in a cost-effective manner . our overall financial performance was once again strong for 2014 , and was characterized by strong treatment volume growth , primarily from acquisitions and non-acquired growth rates , cost control initiatives and productivity improvements in our dialysis business , and solid growth in hcp 's senior capitated members . however , hcp experienced a significant reduction in medicare advantage reimbursement rates in 2014 , which negatively impacted its operating income . in addition , our dialysis segment experienced a large increase in our pharmaceutical costs . some of our major accomplishments and financial operating performance indicators in 2014 and year over year were as follows : · improved clinical outcomes in our u.s. dialysis operations ; · consolidated net revenue growth of approximately 8.8 % . a 5.8 % revenue growth related to our u.s. dialysis segment operations and an increase of 9.6 % in our hcp segment operations ; · an increase of approximately 5.7 % in the overall number of u.s. dialysis related treatments ; · normalized non-acquired u.s. dialysis treatment growth of 5.0 % ; · consolidated operating income growth of approximately 17.1 % ; · an increase of 72,800 in hcp 's senior capitated members ; · added a net total of 105 u.s. dialysis centers and added a total of 18 international dialysis centers ; and · strong operating cash flows of $ 1.459 billion , which have been reduced by approximately $ 269 million of after-tax payments made in connection with the settlement of the 2010 and 2011 u.s. attorney physician relationship investigations . however , we face uncertainty and various challenges in 2015 as we undertake initiatives to mitigate increases in clinical costs that we expect to experience due to inflation and other factors without any corresponding increase in our dialysis medicare reimbursement rates . in addition , congress could still make significant changes to medicare and medicaid under the health care reform legislation that was enacted in the u.s. and there is uncertainty around the potential negative impact of healthcare insurance exchanges . physician practices of prescribing pharmaceuticals and pharmaceutical costs could also have a significant impact on our operating results . we also remain committed to our international expansion plans that will continue to require investment . in addition , if the percentage of our dialysis patients with commercial payors continues to deteriorate or if we experience a decrease in our overall commercial rates , our operating results could be adversely affected . hcp also faces uncertainty in medicare advantage reimbursement rates as the government continues to modify adjustments to the rates . see hcp 's “ net revenues section ” for further details . 60 following is a summary of consolidated operating results for reference in the discussion that follows . the operating results of hcp are included in our operating results effective november 1 , 2012. replace_table_token_7_th the following table summarizes consolidated net revenues : replace_table_token_8_th 61 the following table summarizes consolidated operating income and adjusted consolidated operating income : replace_table_token_9_th ( 1 ) for the years ended december 31 , 2014 and 2013 , we have excluded $ 17 million and $ 397 million , respectively , of accruals related to a loss contingency reserve for the settlement of the 2010 and 2011 u.s. attorney physician relationship investigations . in 2013 , we have also excluded $ 57 million related to a decrease in hcp 's 2013 contingent earn-out obligation and an adjustment of $ 8 million to reduce a tax asset associated with the hcp acquisition escrow provisions . for the year ended december 31 , 2012 , we have excluded $ 86 million of expenses related to a legal settlement and we have also excluded $ 31 million of transaction expenses associated with the acquisition of hcp from operating expenses and operating income . these are non-gaap measures and are not intended as substitutes for the gaap equivalent measures . we have presented these adjusted amounts because management believes that these presentations enhance a user 's understanding of our normal consolidated operating income by excluding certain unusual items which we do not believe are indicative of our ordinary results of operations . as a result , adjusting of these amounts allows for comparison to our normal prior period results . story_separator_special_tag in 2014 , we continued to enter into some commercial contracts covering certain patients that will primarily pay us a single bundled payment rate for all dialysis services provided to these patients . we are continuously in the process of negotiating agreements with our commercial payors , and payors are aggressive in their negotiations . if our negotiations result in overall commercial rate reductions in excess of overall commercial rate increases , this would have a material adverse effect on our operating results . in addition , if there are job losses in the u.s. as a result of a downturn in the economy , or depending upon changes to the healthcare regulatory system , including the impact of health care insurance exchanges , we could experience a decrease in the number of patients covered under commercial plans . approximately 3 % of our dialysis and related lab services revenues for the year ended december 31 , 2014 , were from physician-prescribed pharmaceuticals that are separately billable , with epo accounting for approximately 2 % of our dialysis and related lab services revenues . the impact of physician-prescribed pharmaceuticals on our overall revenues that are separately billable has significantly decreased from prior years primarily as a result of medicare 's single bundled payment system , as well as some additional commercial contracts that pay us a single bundled payment rate . our operating performance with respect to dialysis services billing and collection can also be a significant factor in the average dialysis and related lab services revenue per treatment we recognize and are able to collect . over the past several years we have invested heavily in upgrades to our systems and internal processes that we believe have helped improve our operating performance and reduced our regulatory compliance risks , and we expect to continue to improve these systems and processes . in 2014 , we continued to upgrade our 65 information technology systems and implemented process changes . we are currently upgrading our billing and other systems and modifying our processes to improve our ability to capture the necessary patient characteristics , co-morbidities and certain other factors under medicare 's bundled payment system . we believe this will potentially enable us to capture additional reimbursement amounts from medicare and enhance our overall billing and collection performance . however , as we continue to make upgrades to our systems and processes , or as payors change their systems and requirements , such as changes to medicare 's billing codes , we could experience a negative impact to our cash collection performance which would affect our average dialysis and related lab services revenue per treatment . our dialysis and related lab services revenue recognition involves significant estimation risks . our estimates are developed based on the best information available to us and our best judgment as to the reasonably assured collectability of our billings as of the reporting date based upon our actual historical collection experience . changes in estimates are reflected in the then-current period financial statements based upon on-going actual experience trends , or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies . our annual average dialysis and related lab services revenue per treatment was approximately $ 342 , $ 340 and $ 332 for 2014 , 2013 and 2012 , respectively . in 2014 , the average dialysis and related lab services revenue per treatment increased by approximately $ 2 per treatment primarily from the recognition of certain california medicaid revenue that was previously reserved , an increase in some of our commercial payment rates , partially offset by changes in our commercial payor mix . in 2013 , the average dialysis and related lab services revenue per treatment increased by approximately $ 8 per treatment primarily due to an increase in our medicare reimbursements , net of the impact of sequestration , and an increase in some of our commercial payment rates , partially offset by changes in the commercial payor mix , and a decline in the intensities of physician-prescribed pharmaceuticals that are billed separately . our average dialysis and related lab services revenue per treatment can be significantly impacted by several major factors , including our commercial payment rates ; government payment policies regarding reimbursement amounts for dialysis treatments and pharmaceuticals under medicare 's bundled payment rate system , including our ability to capture certain patient characteristics ; changes in the mix of government and commercial patients , including the number of commercial patients that are either covered under commercial contracts or are out of network ; and changes in the mix and intensities of physician-prescribed pharmaceuticals that are billed separately . the principal drivers of our dialysis and related lab services patient care costs are clinical hours per treatment , labor rates , vendor pricing of pharmaceuticals , utilization levels of pharmaceuticals , business infrastructure costs , which include the operating costs of our dialysis centers , and certain professional fees . however , other cost categories can also represent significant cost variability , such as employee benefit costs , payroll taxes , insurance costs and medical supply costs . our average clinical hours per treatment or productivity levels in 2014 improved slightly compared to 2013 , which was primarily the result of improvements in our internal procedures and processes . we are always striving for improved productivity levels , however , changes in federal and state policies or regulatory billing requirements can lead to increased labor costs in order to implement these new requirements , which can adversely impact our ability to achieve optimal productivity levels . in addition , improvements in the u.s. economy have stimulated additional competition for skilled clinical personnel resulting in slightly higher teammate turnover in 2014 , which we believe negatively affected productivity levels . in 2014 and 2013 , we experienced an increase in our clinical labor rates of approximately 1.5 % and 2.0 % , respectively , as clinical

